Brain
The following list provides a brief description of brain cancer trials that are open for recruitment in Western Australia. If you would like more information please follow the links provided, contact one of the trial sites or speak with your doctor.
Please note that this list is based on information provided to the Cancer Council by WA hospitals and may not include all clinical trials that are running in WA.
Where ‘N/A' appears - this means the lacking information has not been provided to date to the Cancer Council.
CATNON Study
|
Registered Title |
A randomised phase III Trial on concurrent and adjuvant Temozolomide chemotherapy in non 1p/19q deleted anaplastic glioma to evaluate overall survival. |
|
Purpose |
This study looks at the effectiveness of different combinations of treatment with oral Temozolomide chemotherapy and radiotherapy, in people with brain cancer of the type non 1p/19q deleted anaplastic glioma. . |
|
Lay Summary |
Who is it for?
Trial details
The study aims to assess whether
Currently different institutions adopt different strategies of radiation and chemotherapy for treating anaplastic glioma, as the most effective treatment is not known. However some studies suggest that there is an increase in progression free survival when chemotherapy is given after radiotherapy. Many glioma patients deteriorate at the time of progression. Thus prolonging the time to progression may help to keep patients in good clinical condition for longer and improve their quality of life. |
|
WA Trial Sites |
SCGH Medical Oncology |
|
Links |
Acknowledgements: Australia New Zealand Clinical Trials Registry
TROG 08.02 - Glioblastoma Multiforme (GBM)
|
Registered Title |
A Randomised Phase III Study of Temozolomide and Short-Course Radiation versus Short-Course Radiation Alone in the Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients. |
|
Purpose |
The purpose of this study is to compare the effects of receiving temozolomide (a chemotherapy drug) during and after a short course of radiation therapy, compared to receiving a short course of radiation therapy alone for patients with your particular type of brain tumour (GBM). |
|
Lay Summary |
Following surgery for newly diagnosed glioblastoma multiforme (GBM) in elderly patients (>65 years of age), some patients will be deemed unsuitable by their Doctor to receive the standard 30 fraction radiotherapy and temozolomide treatment regimen. Temozolomide is a new drug that has shown to slow the growth of GBM and increase survival of patients in those >65 years of age, when combined with the standard radiotherapy regimen.
The purpose of this study is therefore to compare the effects of receiving temozolomide during and after a short course of radiation therapy compared to receiving a short course of radiation therapy alone in GBM patients older then 65 years of age. Approximately 560 people from Canada, Europe, Australia and New Zealand will take part in this study. We estimate about 30 patients per year from Australia and New Zealand will take part. |
|
WA Trial Sites |
SCGH Radiation Oncology |
|
Links |
[Return to List of Clinical Trials]
